BioPharm International-09-01-2005

BioPharm International

Regulatory Beat: Crawford Faces Policy and Program Challenges

September 01, 2005

Columns and Departments

18

9

The Senate confirmed Lester Crawford in July as the official head of the Food and Drug Administration (FDA). Crawford's nomination had been put on hold as various legislators pressured FDA to approve an over-the-counter version of the "morning-after" pill, Plan B, and to support broader drug importing.

Operations Excellence: BioPharma Operations Excellence

September 01, 2005

Columns and Departments

18

9

Formal process and operation improvement activities are being employed in almost every biopharmaceutical manufacturing company, according to a recent survey conducted by Tefen Ltd and Millipore Corporation. The industry-wide survey was conducted to assess current biopharmaceutical operations excellence (OpEx) trends and needs, as well as OpEx perceptions and expectations related to industry suppliers.

The United Kingdom: Leading the Global Competition for Biotech

September 01, 2005

Articles

18

9

As a company that performs site selection for biopharmaceutical companies worldwide, Fluor Global Location Strategies has witnessed one country truly distinguishing itself from the competition as a worldwide leader in the industry: the United Kingdom. The global competition for biotech investments has been at a fever pitch over the past few years, with varied results.

The Search for Cancer Diagnostic Markers: A Race Against Time

September 01, 2005

Articles

18

9

At this time there are no effective diagnostic tests for cancer that are rapid, economical, highly specific, and highly sensitive. This deficiency means that many cases of malignancy go undetected until long past the time of effective treatment. Much cancer research, including investigations carried out by both the academic and private sector, is focused on combining therapy and diagnostics as "theragnostics."

Final Word: Collaborate to Compete?

September 01, 2005

Columns and Departments

18

9

Daunting but common challenges currently face many biotech, pharmaceutical, and device firms. These companies are encountering a restless public, worried investors, and a skeptical, publicity-hungry Congress that are all concerned about product safety and the reliability of regulators' scrutiny.

From the Editor in Chief: From Leeches to Lawsuits

September 01, 2005

Columns and Departments

18

9

Hurricane Katrina is slamming into the Gulf Coast of the US at the moment, with wind gusts of up to 140 mph. As many as 10,000 residents of New Orleans, LA have taken shelter in the city's Superdome, while others obeyed the mandatory evacuation order and fled to safer ground earlier.